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Abstract: Chronic inflammation is a well-recognized pathogenic factor in tumor initiation and progression. Mice 
lacking the pro-oncogenic transcription factor STAT3 were shown to be protected from both colitis-associated and 
epidermal cancers induced by the AOM/DSS and DMBA/TPA protocols, respectively. However, these murine models 
did not distinguish between the two STAT3 isoforms, the full-length STAT3α, believed to exert most pro-oncogenic 
functions attributed to STAT3, and the shorter STAT3β, often referred to as a dominant-negative, but possessing 
specific transcriptional activities. Here we assessed the contribution of STAT3β to inflammation-driven tumorigen-
esis making use of mice lacking this isoform, but still expressing STAT3α (STAT3Δβ/Δβ). We show that the lack of 
STAT3β leads to exacerbated acute responses to both TPA and DSS, thus confirming its anti-inflammatory role. 
Enhanced inflammation correlates with earlier tumor onset in both the epidermis and the intestine in STAT3Δβ/Δβ 
mice. In contrast, overall tumor development and final tumor burden were unaffected. These results suggest that 
STAT3β, by limiting inflammation during the initial phases of tumorigenesis, contributes to tissue homeostasis and 
counteracts malignant transformation and initial tumor growth. Accordingly, the balance between the two STAT3 
isoforms, likely determined by the complex signaling networks shaping the tumor microenvironment and driving 
tumor transformation and progression, is apparently crucial to determine the initial tumor transformation rates in 
inflammation-associated cancers.
Keywords: STAT3 isoforms, STAT3β, inflammation, inflammation-driven tumorigenesis, colitis-associated cancer, 
AOM/DSS protocol, skin tumorigenesis, DMBA/TPA protocol, genetically modified mice
Introduction
Signal Transducer and Activator of Transcription 
(STAT)3 is an extremely pleiotropic transcrip-
tion factor that is activated downstream of mul-
tiple cytokine and growth factor receptors by 
tyrosine phosphorylation, and displays a tis-
sue- and signal-specific repertoire of target 
genes [1-3]. STAT3 is considered as an onco-
gene, since it is constitutively active in a wide 
variety of tumors and often required for tumor 
cell transformation, survival and proliferation 
[4]. Its activation in tumors mainly occurs down-
stream of aberrantly activated pro-oncogenic 
signals, although activating mutations have 
been recently identified in a subset of hepato-
cellular adenomas [5]. On the other hand, 
STAT3 is also able to act as a tumor suppressor 
under specific conditions, underscoring the bio-
logical complexity of its functions. For example, 
STAT3 gene inactivation was shown to enhance 
tumorigenesis in a model of thyroid adenocarci-
noma [6] and in ApcMin-induced intestinal tumor-
igenesis [7].
STAT3 exists in two alternatively spliced iso-
forms, the full length STAT3α and the truncated 
STAT3β [8]. The latter lacks the C-terminal 
Transcriptional Activation Domain (TAD) and 
has long been considered as a dominant nega-
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tive form. However, others and we have demon-
strated that the β isoform can play unique func-
tions, activating both common and specific rep-
ertoires of STAT3 target genes, and is able to 
rescue the embryonal lethality of a null STAT3 
mutation [8-11]. STAT3β can play opposite 
functions in tumorigenesis. When over-expre- 
ssed, it can oppose the pro-oncogenic effects 
of STAT3α in several tumor cell lines, acting as 
a dominant negative form [4]. Moreover, the 
induction of a splicing switch towards the beta 
isoform leads to apoptosis and cell-cycle arrest 
in STAT3-dependent cell lines that show persis-
tent STAT3 tyrosine phosphorylation, via the 
activation of a unique gene expression signa-
ture [12]. In contrast, STAT3β apparently acts 
as an oncogene by triggering aggressive T cell 
leukemia when overexpressed in transplanted 
bone marrow cells [13]. On the other hand, 
STAT3β appears to act as a suppressor of sys-
temic inflammation. Mice lacking STAT3β are 
more sensitive to endotoxic shock [9, 10], and 
were recently shown to develop exacerbated 
atherosclerosis in the absence of ApoE [14]. 
Accordingly, STAT3β-deficient macrophages 
display enhanced production of inflammatory 
cytokines and reduced levels of the anti-inflam-
matory cytokine IL-10 upon lipopolysaccharide 
(LPS) treatment [10]. These unique properties 
of the beta isoform may contribute to the 
extraordinary functional complexity of STAT3 
under both physiological and pathological 
conditions. 
Continuous, non-resolving inflammation is a 
common feature of the tumor microenviron-
ment and plays a crucial role in both initiation 
and progression of many malignancies [15, 
16]. Accordingly, chronic inflammatory condi-
tions such as inflammatory bowel diseases, 
hepatitis or pancreatitis are well known cancer-
predisposing factors. STAT3 is considered as a 
key player in mediating inflammation-driven 
tumorigenesis, being constitutively activated by 
chronically high levels of the pro-inflammatory 
cytokine IL-6 and participating in a feed-for-
ward loop with IL-6 and the pro-oncogenic tran-
scription factor NF-κB [4, 17]. Indeed, both IL-6 
and STAT3 have been shown to be essential 
pathogenic factors in Colitis-Associated Cancer 
(CAC) [18, 19]. This is modeled in the mouse by 
a single administration of the pro-carcinogen 
azoxymethane (AOM), whose mutagenic effects 
are then revealed by chronic inflammation trig-
gered via repeated treatments with the luminal 
toxin dextran sodium sulphate (DSS) in the 
drinking water [20]. STAT3 is also required for 
tumor development in another well accepted 
tumor model where chronic inflammation plays 
a prominent role, the DMBA/TPA multi-step 
skin carcinogenesis protocol [21, 22]. This con-
sists of a single topical exposure of the murine 
skin to the 7, 12-Dimethylbenz(a)anthracene 
(DMBA) mutagen, followed by repeated applica-
tions of the tumor promoting agent 12-O-te- 
tradecanoylphorbol 13-acetate (TPA). In both 
models, STAT3 plays a prominent role in favor-
ing cell survival upon the mutagenic event, but 
it is also thought to contribute to tumor pro-
gression [18, 19, 22, 23]. However, the specific 
roles played by the alpha and beta isoforms in 
the context of inflammation-associated tumors 
have not been addressed.
Here, we assess the contribution of the STAT3β 
isoform to inflammation-driven carcinogenesis 
by exposing mice specifically lacking STAT3β 
(STAT3Δβ/Δβ) to both the AOM/DSS and the 
DMBA/TPA carcinogenesis protocols. Consis- 
tent with its anti-inflammatory role, in both 
models STAT3Δβ/Δβ mice display enhanced initial 
inflammation and earlier onset of tumor that, 
however, do not correlate with increased final 
tumor burden, supporting the idea that STAT3β 
may play an anti-oncogenic role in inflamma-
tion-driven cancer mainly acting at the earlier 
steps of tumor formation.
Materials and methods
Mice and treatments
STAT3Δβ/Δβ mice were generated as described in 
[10], backcrossed for 5 generation with the 
Balb/c background, maintained in the trans-
genic unit of the Molecular Biotechnology 
Center (University of Turin, Turin, Italy) and 
given water and food ad libitum. Genetic 
screening was performed by PCR as previously 
described [10]. Procedures were conducted in 
conformity with national and international laws 
and policies as approved by the University of 
Turin Ethical Committee. 
DMBA/TPA protocol
The two-stage skin carcinogenesis experiments 
were performed as previously described [22], 
with some modifications. Briefly, eight-weeks 
old STAT3Δβ/Δβ and control female littermates 
were shaved on the back 48h before exposure 
of the skin to DMBA (Sigma Aldrich, 25 µg in 
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200 μg of acetone), followed after two weeks by 
biweekly treatments with TPA (Sigma Aldrich, 4 
µg in 200 μg of acetone) for 42 weeks. Mice 
were monitored for tumor formation weekly. 
Skin papillomas were counted and measured 
with a caliper. Papillomas were collected at the 
end of the study for histopathological evalu- 
ation. 
For acute responses to TPA, twelve-weeks old 
female mice were treated with a single dose of 
TPA (0.1 mM in acetone) or with acetone alone 
on their shaved backs, and sacrificed after 24 
or 72 hours for histopathological analysis. 
Proliferation and inflammation were evaluated 
in blind as follows: Proliferation: (-) epidermis 
1-2 layers, thin stratum corneum and thin or 
absent granular layer; (+/-) some areas display-
ing more than two cell layers in the epidermis; 
(+) epidermis 2-4 cell layers, thicker stratum 
corneum; (++) many cell layers, both stratum 
corneum and granular layer more evident; (+++) 
thick epidermis, stratum corneum and granular 
layer very evident along the entire section; 
Inflammation: (-) none or very few inflammatory 
cells, dispersed into the dermis; (+) few inflam-
matory cells in the adipose tissue and many in 
dermis and epidermis; (++) some detachment 
areas between epidermis and dermis due to 
inflammation, few inflammatory cells in the adi-
pose tissue; (+++) numerous detachment areas 
between epidermis and dermis, aggregates of 
inflammatory cells in the adipose tissue.
AOM/DSS protocol
The CAC tumorigenesis experiments were per-
formed as previously described [24]. Briefly, six-
weeks old STAT3Δβ/Δβ and control male litter-
mates were injected i.p. with AOM (Sigma 
Aldrich, 12.5 mg/kg in PBS), followed by three 
five-days cycles of 2.5% DSS in the drinking 
water (MP Biomedicals, MW 35,000-50,000, 
first and second cycle) or 2% DSS (third cycle) 
with 14 days intervals. Mice were sacrificed at 
day 60 or 80 after AOM injection and their 
intestine prepared as a “Swiss Roll” for subse-
quent analysis [25]. Macroscopic tumors were 
counted and measured (see below).
For acute DSS treatment, mice received water 
with 3% DSS for five days and were sacrificed at 
different times after the end of the treatment 
[26]. Colitis scoring: mice were daily monitored 
for colitis features (see below) and sacrificed at 
0, 5, 7 or 9 days from the beginning of the 
experiment. The colons were removed and their 
lengths measured from the anus to the begin-
ning of the caecum, as an indirect marker of 
inflammation, followed by histopathological 
analysis as above [27]. 
The clinical course of the disease was followed 
daily and represented by a colitis clinical score 
as previously described [27], with some modifi-
cations. The colitis clinical score was obtained 
as the sum of the scores assigned for body 
weight loss (0, none; 1, 1-5%; 2, 5-10%; 3, 
10-20%; 4, more than 20%), stool consistency 
(0, well formed pellets; 2, pasty and semi-
formed stools; 4, liquid stools), and the pres-
ence or absence of fecal blood (0, negative; 2, 
light bleeding; 4, marked bleeding). Accordingly, 
the score can range from 0 (healthy) to 12 
(maximal colitis activity).
Histological analysis and immunohistochem-
istry
For papillomas or TPA treated skins, back skins 
from sacrificed mice were fixed in 4% buffered 
formalin for 24h and embedded in paraffin. 4 
µm thick sections were stained with haematox-
ylin and eosin (H&E) and analyzed in blind by a 
pathologist.
For the colon, Swiss rolls (see above) were fixed 
in 4% buffered formaldehyde for 24h and sub-
sequently embedded in paraffin [25]. Sections 
were stained with H&E and analyzed for tumor 
evaluation and inflammation.
Immunohistochemical analysis were performed 
on paraffinembedded sections (4 µm), with the 
following antibodies: anti-CD3 (Neomarkers, 
RM9107), anti phospho-STAT3 (Tyr705, #9131, 
Cell Signaling Technology), anti-PCNA (sc-56, 
Santa Cruz Biotechnology), anti-CD18 (BMA, 
BioMedicals, Augst, CH), anti-neutrophil (NIMP- 
R14, ab2557, Abcam). Quantification was per-
formed using the Metamorph software (Univer- 
sal Imaging Corporation, Downingtown, PA, 
USA), calculating the ratio between the per-
centage of staining with respect to total tissue 
for each field.
Tumors quantitation
The quantitation of colon polyps was performed 
as previously described [7]. Briefly, median sec-
tions from the entire Swiss rolls were stained 
with H&E and scanned using TissueFaxsTM soft-
ware (TissueGnostics GmbH, Vienna, Austria; 
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www.tissuegnostics.com), and the quantitation 
of total colon area, tumor area and tumor num-
ber performed using the HistoQuestTM (Tissue- 
Gnostics) software.
Real-time PCR
Total RNA was extracted from 0.5 cm portions 
of proximal plus distal colon from DSS treated 
mice using the PureLink Micro-to-Midi total 
RNA Purification System (Invitrogen, Carlsbad, 
CA, USA) and its concentration was determined 
with a NanoDrop™ 1100 (NanoDrop 
Technologies, Wilmington, DE, USA). Total RNA 
was reverse-transcribed with a high capacity 
cDNA reverse transcription kit (#4368813, 
Applied BioSystem) according to manufactur-
er’s instruction and amplified with specific 
primers. Taqman PCR reactions were per-
formed as previously described [28], using the 
Universal Probe Library system (Roche Italia, 
Monza, Italy), and quantified with the Molecular 
Analyst software (Bio-Rad Laboratories). The 
18S rRNA pre-developed TaqMan assay 
(#4319413, Applied Biosystems) was used as 
an internal control. Expression of the target 
genes was calibrated against the values 
obtained in untreated animals (d0).
Specific primers and probes used: IL-6, 5’- 
GCTACCAAACTGGATATAATCAGGA-3’, 5’-CAGGT- 
AGCTATGGTACTCCAGAA-3’, UPL probe #6; MIP-
2, 5’-GAAAATCATCCAAAAGATACTGAACA-3’, 5’- 
CTTTGGTTCTTCCGTTGAGG-3’, UPL probe #26; 
CCL2, 5’-GATCATCTTGCTGGTGAATGAGT-3’, 5’- 
CATCCACGTGTTGGCTCA3’, UPL probe #62; 
COX2, 5’-GATGCTCTTCCGAGCTGTG-3’, 5’-GGAT- 
TGGAACAGCAAGGATTT-3’, UPL probe #45; 
SOCS3, 5’-ATTTCGCTTCGGGACTAGC-3’, 5’-AA- 
CTTGCTTGGGTGACCAT-3’, UPL probe #83.
Statistical analysis
An unpaired t test was used to calculate a P 
value between the specified groups, using the 
GraphPad Prism 5 software (GraphPad Sof- 
tware Inc., San Diego, CA, USA). Statistically sig-
nificant P values and symbols: P ≤ 0.05 (*), P ≤ 
0.01 (**), P ≤ 0.001 (***).
Results
STAT3Δβ/Δβ mice display enhanced skin inflam-
mation upon TPA acute treatment
We have previously shown that STAT3Δβ/Δβ mice 
are more susceptible to LPS-induced acute 
inflammation, displaying enhanced production 
of inflammatory cytokines such as IL-6 and 
TNFα and increased tissue damage. In order to 
investigate acute inflammatory responses in 
the skin, STAT3Δβ/Δβ mice and control littermates 
were shaved, treated with TPA and sacrificed 
after 24 or 72 hours for histological analysis. 
No morphological differences were detected 
between untreated mice (Figure 1A, 0h). 
Inflammation was readily detectable at 24 
hours after TPA treatment in mice of both geno-
types but particularly marked in the STAT3Δβ/Δβ 
mice, where inflammatory cells can be appreci-
ated to abundantly infiltrate the dermal-epider-
mal junction, the dermis and, to a minor extent, 
the subcutaneous adipose tissue (Figure 1A 
and 1B). Inflammation was significantly decre- 
ased at 72 hours in wild type mice while remain-
ing high in the STAT3Δβ/Δβ skins, in particular in 
the lower dermis and in the subcutaneous adi-
pose tissue. Increased inflammatory infiltrate 
was also detected by immunostaining with the 
pan-leukocyte marker CD18 (Figure 1C). As 
expected, TPA treatment induced cell prolifera-
tion, as judged by the increased number of epi-
dermal keratinocyte layers (see Materials and 
Methods section), as well as by the increased 
percentage of PCNA+ cells in both the dermis 
and the epidermis (Figure 1D). Proliferation 
was however equivalent in mice of the two gen-
otypes. In agreement with the enhanced inflam-
mation, STAT3Δβ/Δβ mice displayed higher phos-
phorylation levels of STAT3α, particularly in the 
dermis (Figure 1E). These data suggest that 
STAT3Δβ/Δβ mice are more susceptible to TPA-
induced acute inflammation than their STAT3WT/
WT controls.
Earlier onset of skin papillomas in STAT3Δβ/Δβ 
mice
To assess whether the enhanced inflammation 
and the high levels of activation of the STAT3α 
isoform observed in the STAT3Δβ/Δβ mice in 
response to TPA correlates with increased sus-
ceptibility to inflammation-driven skin cancer, 
mice were subjected to the DMBA/TPA multi-
step carcinogenesis protocol [21]. In the 
absence of STAT3β, there was an earlier onset 
of squamous cells papillomas (SCPs) (week 11 
versus week 17 after the first TPA exposure). 
Moreover, while 40% of the STAT3WT/WT mice 
had not developed SCPs at the end of the 
experiment (week 42), only 14% of the STAT3Δβ/
Δβ mice were still papilloma-free (Figure 2A), 
suggesting enhanced tumor incidence. Howev- 
Stat3beta in inflammation-driven tumorigenesis
488 Am J Cancer Res 2014;4(5):484-494
Stat3beta in inflammation-driven tumorigenesis
489 Am J Cancer Res 2014;4(5):484-494
er, the number and size of SCPs detected per 
mouse, although variable, was overall equiva-
lent in mice of the two genotypes (Figure 2B). 
All lesions displayed the histological features of 
benign papillomas (Figure 2C), with the excep-
tion of one in situ carcinoma detected in one 
out of 14 STAT3Δβ/Δβ mice analyzed (not shown). 
These data suggest that although in the ab-
sence of STAT3β, tumor formation is accelerat-
becoming comparable to those of the wild type 
controls, suggesting resolution of the inflam-
mation. Immunohistochemical analysis could 
clearly show significantly enhanced infiltration 
of both CD3+ T lymphocytes and Gr1+ granulo-
cytes in colons derived from STAT3Δβ/Δβ mice at 
day 5 of treatment, confirming higher inflamma-
tion (Figure 4A and 4B). Interestingly, the num-
ber of cells expressing activated STAT3α, ini-
Figure 1. Increased skin inflammation in response to TPA in STAT3Δβ/Δβ mice. The shaved skins of STAT3WT/WT and 
STAT3Δβ/Δβ mice (0h, n=4; 24h and 72h, n=6 per genotype) topically treated with 0.1 mM TPA were excised at the in-
dicated time points and stained with Haematoxylin and Eosin (H&E) (A). Representative images are shown with the 
indicated magnifications. (B) The degree of proliferation (P) or inflammation (I) was calculated as described in the 
Materials and Methods section. Results are representative of two independent experiments each with 3 mice/geno-
type. (C-E) Representative images (20x) of IHC stainings with anti-CD18 (C), anti-PCNA (D) or anti-phosphoSTAT3 
(E) antibodies. Epi, epidermis; Der, dermis. Quantification: the histograms represent the mean±SEM of 3 fields 
per sample (n=3), where the extent of the positive area over the total area was calculated using the Metamorph 
software, separately for the epidermis and the dermis. Grey bars, STAT3WT/WT mice; black bars, STAT3Δβ/Δβ mice. The 
asterisks indicate statistically significant differences between the indicated groups. *P ≤ 0.05, **P ≤ 0.01, ***P 
≤ 0.001.
Figure 2. STAT3Δβ/Δβ mice show earlier papilloma onset but unal-
tered tumor load. STAT3WT/WT and STAT3Δβ/Δβ mice were treated with 
DMBA/TPA as described and observed for squamous cell papil-
loma (SCP) development for 42 weeks. A. Shows the percentage 
of papilloma-free mice. Grey line, STAT3WT/WT mice (n=15); black 
line, STAT3Δβ/Δβ mice (n=14). B. Shows the number and mean 
diameter±SD of SCPs per mouse. C. Representative SCPs images 
from mice of the indicated genotypes.
ed and parallels the enhanced inflam-
matory response to TPA, the overall 
tumor progression is apparently not 
affected.
STAT3Δβ/Δβ mice display exacerbated 
colitis after DSS treatment
To assess acute responses to DSS-
induced colon inflammation, STAT3Δβ/Δβ 
mice and control littermates were given 
one five-days cycle of DSS in the drink-
ing water and sacrificed at different time 
points (day 0, 5, 7 and 9 from the begin-
ning of treatment). STAT3Δβ/Δβ mice were 
significantly more susceptible to acute 
DSS-induced inflammation. Shortening 
of the colon, a typical colitis marker, was 
significantly more pronounced at days 5 
and 7 (Figure 3A), correlating with a sig-
nificantly higher colitis clinical score, 
which considers bleeding, weight loss 
and stool consistency as described in 
the Materials and Methods section 
(Figure 3B). Increased inflammation 
was also confirmed by the higher expres-
sion levels of mRNAs encoding pro-
inflammatory markers such as IL-6, 
MIP2, CCL2 and COX2 (Figure 3C). 
Expression of the classical STAT3 target 
gene SOCS3, a negative regulator of the 
JAK-STAT pathway, was also enhanced 
(Figure 3C). Interestingly, by day 9 both 
colon length and clinical score improved 
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tially lower in the STAT3Δβ/Δβ mice, increased 
sharply upon DSS treatment to become equiva-
lent to those detected in the wild type litter-
mates (Figure 4C, see fold induction). Finally, 
DSS-induced proliferation was similar in mice 
of the two genotypes, as shown by equivalent 
numbers of PCNA+ cells (Figure 4D). 
Colitis-driven carcinogenesis in 
STAT3WT/WT and STAT3Δβ/Δβ mice
In order to assess whether the 
absence of STAT3β, resulting in the 
observed increased sensitivity to 
DSS-induced colon inflammation, 
could enhance susceptibility to 
colitis associated cancer (CAC), we 
took advantage of the AOM/DSS 
CAC model [20, 26], injecting mice 
of both genotypes with AOM, fol-
lowed by three five-days cycles of 
DSS in the drinking water (Figure 
5A). In a first round of experiments, 
mice were sacrificed at day 60 for 
the analysis of tumor load. 
Histological analysis showed that 
at this stage 6 out of 18 (33.4%) 
STAT3WT/WT mice were still tumor-
free, against only 2 out of 12 
(16.7%) STAT3Δβ/Δβ mice (Figure 
5B). This increased incidence was 
likely due to an earlier onset of 
tumor lesions in the absence of 
STAT3β, since both tumor number 
and tumor area per mouse were 
comparable between animals of 
the two genotypes, suggesting 
equivalent grown rates and pro-
gression (Figure 5C and 5D). 
Accordingly, the penetrance was 
100% in mice of both genotypes 
when a second round of experi-
ments was performed where mice 
were sacrificed 20 days later, and 
again no differences in tumor bur-
den were observed (Figure 5C and 
5D). Histological analysis per-
formed on colon samples at day 80 
showed no difference in tumor 
morphology between the two geno-
types (Figure 5E and 5F). Thus, the 
stronger inflammatory response to 
DSS displayed by the STAT3Δβ/Δβ 
mice correlated with an earlier 
tumor onset but did not affect over-
Figure 3. Exacerbated DSS-induced colitis in STAT3Δβ/Δβ mice. Mice treat-
ed for five days with 2.5% DSS in the drinking water were sacrificed at 
different times (day (d) 0, 5, 7, 9). Colon length (A) and clinical score (B) 
were evaluated as described in the Materials and Methods section. Colon 
length, STAT3WT/WT mice, n= 9 (d0), n=6 (d5), n=7 (d7 and d9); STAT3Δβ/Δβ 
mice, n=9 (d0), n=5 (d5), n=6 (d7) and n=4 (d9). Clinical score, STAT3WT/
WT mice, n=9 (d5), n=6 (d7) and n=12 (d9); STAT3Δβ/Δβ mice, n=8 (d5), 
n=5 (d7) and n=9 (d9). (C) Taqman PCR analysis of the expression of IL-
6, MIP-2, CCL2, COX2, and SOCS3, normalized to 18S RNA as an internal 
control, in the DSS-treated colons. Data are expressed as induction fold 
of STAT3Δβ/Δβ respect to STAT3WT/WT mice, and are the mean±SEM of 3 
samples/genotype. Asterisks indicate statistically significant differences 
between the indicated goups. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
all tumor progression, similar to what observed 
in the DMBA/TPA skin carcinogenesis model.
Discussion
Tumor-promoting inflammation has been 
recently recognized as an important enabling 
characteristic of cancer, contributing to multi-
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ple hallmark features of tumor cells by releas-
ing mutagenic reactive oxygen species, as well 
as by supplying extrinsic factors that help cell 
survival and growth, thus promoting tumor ini-
tiation. On the other hand, the intrinsic inflam-
matory programs elicited by oncogenic muta-
tions in tumor cells contribute shaping a tumor-
promoting microenvironment rich in factors 
that induce cell survival, proliferation, angio-
TPA was sufficient to induce more abundant 
and longer lasting inflammatory skin infiltration 
in STAT3Δβ/Δβ mice, correlating with a higher 
increase of cells displaying tyrosine-phosphory-
lated STAT3 in the dermis with respect to wild 
type mice. Proliferation, which usually follows 
damage/inflammation to favour healing and is 
considered as a fundamental step in the tumor-
promoting effects of TPA, was however equiva-
Figure 4. Increased DSS-induced inflammation in STAT3Δβ/Δβ mice. Colon 
sections from acutely DSS treated mice (see legend to Figure 3) were 
stained with the indicated antibodies to detect infiltrating CD3+ T lympho-
cytes (A) Gr1+ granulocytes (B), p-Y-STAT3+ (C) or PCNA+ (D) cells. Repre-
sentative images are shown at low magnification (2x), with 20x insets. The 
histograms represent the mean±SEM of 6 fields per sample where the 
extent of the positive area over the total epidermal area was calculated us-
ing the Metamorph software. Grey bars, STAT3WT/WT mice (n=3); black bars, 
STAT3Δβ/Δβ mice (n=3). The induction fold between the values obtained 
from treated and untreated mice is indicated below the images. Note that 
d9 is shown for the PCNA staining because no increase was detected at 
d5. Asterisks indicate statistically significant differences between the per-
centages of positive cells (histograms) or the induction folds (pictures) of 
the indicated groups. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
genesis, motility and invasion, 
thus stimulating tumor progres-
sion [15, 16]. 
Both IL-6 and its main down-
stream mediator STAT3 have 
been identified as main players in 
regulating tumor-associated in- 
flammation and the cross-talk 
between the microenvironment 
and tumor cells [4, 29, 30]. In 
particular, STAT3 deletion in 
either keratinocytes or intestinal 
epithelial cells was shown to pro-
tect mice from tumor develop-
ment in both the DMBA/TPA- and 
AOM/DSS-mediated carcinogen-
esis models of the skin and colon 
[18, 19, 22, 23]. STAT3 acted at 
multiple levels in both models, 
mediating both survival to the 
mutagenic insult (tumor initiation 
stage) and subsequent prolifera-
tion (tumor promotion stage). 
Although the relative contribution 
of the two STAT3 isoforms, alpha 
and beta, to inflammation-driven 
tumor onset and progression has 
never been assessed, STAT3β 
has long been considered as a 
dominant negative form of the 
pro-oncogenic activities of the 
alpha isoform [4]. On the other 
hand, while STAT3α can act both 
as a pro- and anti-inflammatory 
factor, depending on the activat-
ing signal, STAT3β functions 
appear to be prominently anti-
inflammatory [9, 10, 14]. This is 
confirmed by our observation 
that mice specifically lacking the 
STAT3β isoform display exacer-
bated acute inflammatory res- 
ponses to both TPA and DSS. 
Indeed, a single application of 
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lent in both the dermis and epithelium of mice 
of the two genotypes. Likewise, STAT3Δβ/Δβ mice 
exhibited enhanced colitis symptoms and sig-
nificantly more extensive infiltration of both 
granulocytes and T lymphocytes in the colon 
mucosa as compared to their wild type litter-
mates upon a single DSS cycle. This is reminis-
cent of the more dramatic DSS-induced colitis 
observed in mice lacking STAT3 in the intestinal 
epithelial cells, which may therefore be at least 
partly due to the lack of the beta isoform. Under 
this scenario of increased inflammation and 
high STAT3α activity, a higher tumor incidence/
burden upon application of the carcinogenesis 
protocols (DMBA/TPA and AOM/DSS) could be 
expected. Indeed, in both models a trend 
towards an earlier onset of tumor lesions was 
observed, likely as a consequence of the higher 
concentration of inflammatory mediators in the 
absence of STAT3β. Accordingly, we have 
recently shown that even low levels of constitu-
tive STAT3α activation in the absence of STAT3β 
can serve as a first hit in the process of malig-
nant transformation, making the cells exqui-
sitely sensitive to mutagenic insults [31]. 
However, the initial enhanced inflammation 
was rapidly normalized, and the overall tumor 
burden per mouse and the mean tumor size/
tumor area were similar in the presence or 
absence of STAT3β, in line with the equivalent 
proliferation levels observed. These results 
suggest that also in cancer STA3β is not a phys-
iological dominant negative factor for STAT3α 
unless it is overexpressed. Thus, while confirm-
ing the potent anti-inflammatory role of STAT3β 
and highlighting its potential oncosuppressive 
role in the initiation phases of skin and colon 
tumorigenesis, our data suggest that the 
effects of the activation of STAT3α in the 
absence of the counteracting STAT3β activity 
are not as dramatic as could be expected, in 
particular in driving tumor progression. For 
CAC, this observation may be partly explained 
by the observation that the colons of DSS-
treated STAT3Δβ/Δβ mice displayed higher ex- 
pression levels of the JAK-STAT negative feed-
back factor SOCS3 (Figure 3C), a well-recog-
nized specific STAT3α target that is believed to 
act as an oncosuppressor in CAC [10, 32]. Thus, 
elevated SOCS3 levels in the STAT3Δβ/Δβ mice 
could be involved in counterbalancing the 
potentially pro-oncogenic effects of higher 
inflammation and unchecked STAT3α activity.
Fine tuning of the degree and length of inflam-
mation is fundamental to warrant resolution 
Figure 5. AOM/DSS treatment triggers earlier colonic tu-
mor onset in STAT3Δβ/Δβ mice. (A) Schematic overview of 
the experimental model. Mice were injected once i.p. with 
AOM (day 1, 12.5 mg/kg), and received the indicated per-
centage of DSS in the drinking water for three five-days 
cycles starting from five days later (black squares), with 2 
weeks regular water intervals. Mice were then sacrificed 
at day 60 or day 80, as indicated. (B) Percentage of tumor 
free mice of the two genotypes at day 60 of treatment. (C, 
D) Mean±SEM of the number of tumors per square centi-
meter (C) and of the tumor area (D) in mice sacrificed at 
d60 and d80, as indicated. Grey bars, STAT3WT/WT, n=12 
(d60), n=13 (d80); black bars, STAT3Δβ/Δβ, n=13 (d60), 
n=11 (d80). The asterisks indicate statistically significant 
differences between the indicated groups. *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. (E, F) Representative images of H&E 
staining on colon samples from mice of the indicated geno-
types at a magnification of 2.5X (E) and 20X (F).
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without promoting tumorigenesis. Our results 
suggest that the balance between the activat-
ed alpha and beta isoforms of STAT3, deter-
mined by the interplay between the complex 
signaling networks activated in the tumor 
microenvironment, plays an important role in 
shaping the inflammatory responses and has a 
major impact on the initial degree of malignant 
transformation.
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